Detection of liver disease in injection drug users

Journal of Addictive Diseases

Volumn 27, Issue 2, 2008, Pages 19-24

  Thomas, David L ^a   Sulkowski, Mark S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biopsy; HCV; Injection drug use; Liver disease; Screening

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; ILLICIT DRUG;

ALCOHOL CONSUMPTION; DISEASE DURATION; DRUG ABUSE; DRUG USE; ELASTOGRAPHY; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER DISEASE; REVIEW; VIRUS HEPATITIS; ARTICLE; BIOPSY; DISEASE COURSE; HEALTH CARE PLANNING; LIVER; LIVER CIRRHOSIS; LIVER FAILURE; MASS SCREENING; PATHOLOGY; RADIOGRAPHY; SUBSTANCE ABUSE;

BIOPSY; DISEASE PROGRESSION; ELASTICITY IMAGING TECHNIQUES; HEALTH PLANNING GUIDELINES; HEPATITIS C; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER DISEASES; LIVER FAILURE; MASS SCREENING; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 52049116123     PISSN: 10550887     EISSN: 15450848     Source Type: Journal    
DOI: 10.1300/J069v27n02_03     Document Type: Review

References (36)

1. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: The prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996; 86:655-661.
2. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284:450-456.
3. Jin A, Bardsley J. Intravenous drug use and hepatitis A: an investigation of an outbreak. Can J Public Health 1990; 81:79-81.
4. Akriviadis EA, Redeker AG. Fulminant hepatitis A in intravenous drug users with chronic liver disease. Ann Intern Med 1989; 110:838-839.
5. Wang C, Vlahov D, Galai N, Cole SR, Bareta J, Pollini R et al. The effect of HIV infection on overdose mortality. AIDS 2005; 19:935-942.
6. Selik RM, Byers RH, Jr., Dworkin MS. Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999. J Acquir Immune Defic Syndr 2002; 29:378-387.
7. Wang C, Vlahov D, Galai N, Cole SR, Bareta J, Pollini R et al. The effect of HIV infection on overdose mortality. AIDS 2005; 19:935-942.
8. Wanless IR, Dore S, Gonipath N, Tan J, Cameron R, Heathcote EJ et al. Histopathology of cocaine hepatotoxicity. Gastroenterology 1990; 98:497-501.
9. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepa-tology 1981; 1:431-435.
10. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24:289-293.
11. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696-699.
12. Perrillo RP. The role of liver biopsy in hepatitis C. Hepatology 1997; 26:57S-61S.
13. Goldin RD, Goldin JG, Burt AD, Dhillon PA, Hubscher S, Wyatt J et al. Intra-observer and inter-observer variation in the histopathological assessment of chronic viral hepatitis. J Hepatol 1996; 25:649-654.
14. McGill DB, Rakela J, Sinsmeister AR, Ott BJ. A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 1990; 99:1392-1400.
15. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-2618.
16. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10-12, 2002. Hepatology 2002; 36: S3-20.
17. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39:1147-1171.
18. Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology 2004; 39:857-861.
19. Schuppan D, Stolzel U, Oesterling C, Somasundaram R. Serum assays for liver fibrosis. J Hepatol 1995; 22:82-88.
20. Wong VS, Hughes V, Trull A, Wight DG, Petrik J, Alexander GJ. Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection. J Viral Hepat 1998; 5:187-192.
21. Teare JP, Sherman D, Greenfield SM, Simpson J, Bray G, Catterall AP et al. Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis. Lancet 1993; 342: 895-898.
22. Rai R, Wilson LE, Astemborski J, Anania F, Torbenson M, Spoler C et al. Severity and correlates of liver disease in hepatitis C virus-infected injection drug users. Hepatology 2002; 35:1247-1255.
23. Gordon SC, Fang JW, Silverman AL, McHutchison JG, Albrecht JK. The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C. Hepatology 2000; 32:400-404.
24. McCormick S, Goodman ZD, Maydonovitch CL, Sjogren MH. Evaluation of liver histology, ALT elevation, and HCV-RNA titer in patients with chronic hepatitis C. Am J Gastroenterol 1996; 91:1516-1522.
25. Persico M, Persico E, Suozzo R, Conte S, De Seta M, Coppola L et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000; 118:760-764.
26. Mathurin P, Moussalli J, Cadranel JF, Thibault V, Charlotte F, Dumouchel P et al. Slow progression rate of fibrosis in hepatitis C virus patients with persis- tently normal alanine transaminase activity. Hepatology 1998; 27:868-872.
27. Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology 1988; 95:734-739.
28. Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998; 93:44-48.
29. Oberti F, Valsesia E, Pilette C, Rousselet MC, Bedossa P, Aube C et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 1997; 113:1609-1616.
30. Matsumura H, Moriyama M, Goto I, Tanaka N, Okubo H, Arakawa Y. Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C-a study of 527 patients at one establishment. J Viral Hepat 2000; 7:268-275.
31. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357:1069-1075.
32. Kanzler S, Baumann M, Schirmacher P, Dries V, Bayer E, Gerken G et al. Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta. J Viral Hepat 2001; 8:430-437.
33. Gebo KA, Chander G, Jenckes MW, Ghanem KG, Herlong HF, Torbenson MS et al. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology 2002; 36:S84-S92.
34. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128:343-350.
35. Fahey BJ, Koziol DE, Banks SM, Henderson DK. Frequency of nonparenteral occupational exposures to blood and body fluids before and after universal precautions training. Amer J Med 1991; 90:145-153.
36. Strathdee SA, Latka M, Campbell J, O'Driscoll PT, Golub ET, Kapadia F et al. Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. Clin Infect Dis 2005; 40 Suppl 5:S304-S312.